Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Rheumatol Ther. 2023 Feb;10(1):73-93. doi: 10.1007/s40744-022-00500-6. Epub 2022 Oct 13.
Rheumatol Ther. 2023.
PMID: 36227530
Free PMC article.
Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN.
López-Romero P, Martinez-Gamboa L, Bang H, de la Torre I, Holzkämper T, Feist E.
López-Romero P, et al. Among authors: holzkamper t.
Arthritis Res Ther. 2020 Aug 18;22(1):193. doi: 10.1186/s13075-020-02284-y.
Arthritis Res Ther. 2020.
PMID: 32811536
Free PMC article.
Item in Clipboard
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Emery P, Durez P, Hueber AJ, de la Torre I, Larsson E, Holzkämper T, Tanaka Y.
Emery P, et al. Among authors: holzkamper t.
Arthritis Res Ther. 2021 Jan 4;23(1):3. doi: 10.1186/s13075-020-02379-6.
Arthritis Res Ther. 2021.
PMID: 33397481
Free PMC article.
Review.
Item in Clipboard
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
Taylor PC, Chen YF, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y.
Taylor PC, et al. Among authors: holzkamper t.
Rheumatol Ther. 2023 Apr;10(2):463-476. doi: 10.1007/s40744-022-00529-7. Epub 2023 Jan 20.
Rheumatol Ther. 2023.
PMID: 36662442
Free PMC article.
Item in Clipboard
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, Daniele F, Brnabic A, Reed C, Wilhelm S, Holzkämper T, Schuster C, Puig L.
Lynde C, et al. Among authors: holzkamper t.
Adv Ther. 2023 Mar;40(3):869-886. doi: 10.1007/s12325-022-02379-9. Epub 2022 Dec 14.
Adv Ther. 2023.
PMID: 36515803
Free PMC article.
Item in Clipboard
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Kirkham BW, Egeberg A, Behrens F, Pinter A, Merola JF, Holzkämper T, Gallo G, Ng KJ, Bolce R, Schuster C, Nash P, Puig L.
Kirkham BW, et al. Among authors: holzkamper t.
Rheumatol Ther. 2023 Oct;10(5):1127-1146. doi: 10.1007/s40744-023-00553-1. Epub 2023 Jul 3.
Rheumatol Ther. 2023.
PMID: 37400681
Free PMC article.
Review.
Item in Clipboard
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
Kameda H, Hagimori K, Morisaki Y, Holzkämper T, Konomi A, Dobashi H.
Kameda H, et al. Among authors: holzkamper t.
Rheumatol Ther. 2023 Dec;10(6):1683-1703. doi: 10.1007/s40744-023-00605-6. Epub 2023 Oct 19.
Rheumatol Ther. 2023.
PMID: 37858007
Free PMC article.
Item in Clipboard
Cite
Cite